What are the treatment options for MDS
Treatment Options for MDS
According to the NCCN Guidelines for Myelodysplastic Syndromes, treatment depends on your risk level and specific situation.
Lower-Risk MDS (Very-Low, Low, or Intermediate-Risk)
Supportive Care:
- Blood transfusions for anemia
- Growth factors to boost blood counts
- Iron, folate, or B12 replacement if needed
For Anemia Specifically:
- Lenalidomide (if you have del(5q) deletion)
- Imetelstat (preferred option for ring sideroblasts with SF3B1 mutation)
- Luspatercept-aamt (for certain anemia patterns)
- Erythropoiesis-stimulating agents (ESAs) like epoetin alfa or darbepoetin alfa
- G-CSF (growth factor)
Other Options:
- Immunosuppressive therapy (IST) with ATG or cyclosporin A for select patients
- Eltrombopag for severe low platelet counts
Higher-Risk MDS
- Hypomethylating agents: Azacitidine or Decitabine (these slow cancer cell growth)
- IDH inhibitors: Ivosidenib (if IDH1 mutation) or Enasidenib (if IDH2 mutation)
- Stem cell transplant (for eligible patients)
- Clinical trials
If Disease Progresses or Doesn't Respond
Your doctor may switch to higher-risk treatment strategies or consider stem cell transplant.
Your oncologist will determine which approach fits YOUR specific situation based on your blood counts, mutations, and overall health.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Myelodysplastic Syndromes — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated September 25, 2026. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Myelodysplastic Syndromes (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with treatment for MDS patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about MDS
- What are the standard first-line treatment options for MDS
- What does PD-L1 expression mean for my MDS treatment options
- How does KRAS mutation affect treatment options for MDS
- Is proton therapy an option for MDS
- What fertility preservation options exist before MDS treatment in young adults
- My MDS came back — what are my options now
- How will I know if my MDS treatment is working
- Can I get vaccinated during MDS treatment